Valbiotis has announced that it will hold a Joint Shareholders’ Meeting on May 5, 2022.

La Rochelle, France – (BUSINESS WIRE) – Regulatory News:

Valbiotis (FR0013254851 – ALVAL, Eligible PEA / PME) (Paris: ALVAL) is a research and development company working on scientific innovation to prevent and combat metabolic and cardiovascular diseases, and a joint general meeting on May 5th. Announced to hold shareholders of. , 2022 and the steps to make the preparatory documents available or to reference them.

The general meeting of shareholders will be held at the following locations.

ENCAN Area – Quai Louis Prunier – 17000 La Rochelle

May 5, 2022 5 pm

It is essential that you have an admission card and ID to attend the General Assembly.

The advance notice of the meeting was posted on our website and was published in the Journal of the French Republic “BALO” (https://www.journal-officiel.gouv.fr) on March 28, 2022.

Notices of the meeting, including the agenda and the text of the resolution, as well as conditions for attending and voting at the General Assembly, will be posted on our website and will be posted on our website in the mandatory legal announcement newsletter “BALO” (https://www.journal). -officiel.gouv.fr) April 15, 2022, Bulletin N ° 45.

All documents referred to in Section R. 22-10-23 of the French Commercial Code in connection with the Joint General Assembly on May 5, 2022 can be found on the Valbiotis website in the next section. www.valbiotis.com/general -Meeting /. These may also be available at our registration office or may be sent to the following address upon request: [email protected]

Documents and information regarding the general meeting of shareholders will be made public to shareholders under the conditions stipulated by the rules in force.

In the evolving context of the COVID-19 epidemic and its fight against its epidemic, the procedures for hosting and attending this conference may vary depending on health, regulation, and legal obligations. Shareholders should regularly refer to the section dedicated to the 2022 General Assembly on our website at www.valbiotis.com/assemblees-generales/. This section can be updated to specify the final conditions for attending the meeting according to the above requirements.

About Barbiotis

Valbiotis is a research and development company committed to scientific innovation to combat and prevent metabolic and cardiovascular diseases that meet unmet medical needs.

Valbiotis takes an innovative approach and develops a new class of health nutrition products designed to reduce the risk of major metabolic diseases based on a multi-target approach enabled by the use of terrestrial and marine plants. By doing so, we aim to revolutionize health.

The product is intended to be licensed to players in the world of health.

Founded in La Rochel in early 2014, the company has built numerous partnerships with the best academic centers. The company has established three sites in France, Perigny, La Rochelle (17) and Lion (63), and has a subsidiary in Quebec (Canada).

Valbiotis, a member of the “BPI Excellence” network and benefiting from the BPI “Innovative Company” label, also has the status of “Young Innovative Company” and has been awarded the European Regional Economic Development Fund for research programs. We receive a great deal of financial support from the European Union. (ERDF). Valbiotis is a company covered by PEA-PME.

For more information on Valbiotis, please visit www.valbiotis.com.

Name: Barbiotis

ISIN code: FR0013254851

Mnemonic code: ALVAL

EnterNext © PEA-PME150

This press release contains forward-looking statements regarding the purpose of Valbiotis. Valbiotis believes that these predictions are based on the information and reasonable assumptions that Valbiotis currently has. However, these do not guarantee future performance and are questioned by a certain number of risks and uncertainties, including those described in economic conditions, changes in financial markets, and approved Valbiotis Universal Registration Documents. It may be seen. Autorité des marchés financiers (AMF), July 27, 2021 (filing number R 21-039). This document is available on our website (www.valbiotis.com).

This press release and the information contained therein do not constitute an offer to sell or subscribe to Valbiotis shares or financial securities, or to solicit purchase or subscription orders in any country.

contact address

Corporate Communication / Barbiotis

Carol Roche / Mark Deloney

+33 5 46 28 62 58

[email protected]

Financial Communication / Actifin

Stephan lewies

+33 1 56 88 11 14

[email protected]